Kardigan extends biotech’s streak of big IPOs with $400M haul

Kardigan has successfully raised $400 million in its initial public offering (IPO), marking a significant milestone in the biotech sector. This achievement brings the total number of biotech firms that have raised at least $400 million in IPO proceeds to four in 2026, the highest tally in a single year since 2021, according to data from BioPharma Dive.

This resurgence in large biotech IPOs reflects a growing investor confidence in the sector, particularly in companies focused on innovative therapies such as cardiology. The influx of capital is likely to bolster research and development efforts, enabling firms to advance their pipelines and potentially bring new treatments to market. As the industry continues to attract substantial funding, it signals a robust environment for biotech innovation and growth, which may reshape the competitive landscape in the coming years.